Evaluates the incidence and outcomes of t-MN in patients with advanced EOC receiving PARPi, suggesting increased risks.
PARPi, a standard of care in advanced EOC, are linked to increased t-MN risk, including myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). Our aim was to evaluate the incidence, clinical characteristics and outcomes of patients developing PARPi-associated t-MN.
No takes yet. Share an insight, caveat, or question.
Sepulveda et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: